Clareo Health | Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures;
Diagnosed with PTCL according to the 2022 revised WHO lymphoma classification standards based on pathological diagnosis by the research center
Using the Lugano 2014 lymphoma efficacy evaluation criteria, the patient must have at least one measurable or evaluable lesion
Age ≥ 18 years
Expected survival greater than 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Adequate organ and bone marrow function
You may not be if
Accompanied by hemophagocytic lymphohistiocytosis (HLH)
Lymphoma involvement in the central nervous system or meninges
Active infections
Uncontrolled clinical cardiac symptoms or diseases
Currently using (or unable to stop at least one week prior to the first dose) a known CYP3A strong inducer or strong inhibitor.
Currently using vitamin K antagonists, antiplatelet drugs, anticoagulants (or unable to stop them within one week prior to the start of the study treatment).
History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
Patients with mental disorders or those unable to provide informed consent
